Know Cancer

or
forgot password

A Multicenter, Open-label, Single-arm Study of the Efficacy and Safety of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites


Phase 2
18 Years
N/A
Not Enrolling
Female
Ovarian Neoplasms

Thank you

Trial Information

A Multicenter, Open-label, Single-arm Study of the Efficacy and Safety of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites


The study consisted of:

- A 30-day screening phase prior to Day 1

- Day 1 registration and pre-treatment paracentesis

- Aflibercept administration within 1-day of registration

- Two-week study treatment cycles (for efficacy data, the cut-off date was 6 months
post-registration

- A 60-day post-treatment follow-up phase

During the study, participants were treated with Aflibercept study treatment through the
duration of the study unless they met one the following criteria for discontinuation:

- Participant (or legal representative) chose to withdraw from treatment

- The investigator or sponsor thought that continuation of the study would be detrimental
to the participants well-being

- Participant had intercurrent illness that prevented further administration of
investigational product (IP)

- Participant had more than 2 IP dose reductions

- Participant had unacceptable adverse events (AEs)

- Participant had arterial thromboembolic events, including cerebrovascular accidents,
myocardial infarctions, transient ischemic attacks, new onset angina, or worsening of
preexisting angina

- Participant required surgical intervention for intestinal obstruction or
gastrointestinal perforation


Participants that met the following criteria were eligible.

Inclusion Criteria:



- Symptomatic malignant ascites resulting from advanced ovarian epithelial cancer
(including fallopian tube and primary peritoneal adenocarcinoma) that required at
least 3 previous therapeutic paracenteses at a frequency of 1 to 4 paracenteses per
month for management.

- Platinum resistant disease defined by relapse or progression of disease during or
after treatment, or drug intolerance.

- Topotecan- and/or liposomal doxorubicin-resistant disease defined by relapse or
progression of disease during or after treatment, or drug intolerance.

Exclusion Criteria:

- Peritoneovenous or other type of shunt that was placed for the management of ascites

- Prior treatment with a VEGF or VEGF receptor inhibitor

- Uncontrolled hypertension

The above information is not intended to contain all considerations relevant to
participation in a clinical trial.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Percentage of Participants With a Repeat Paracentesis Response (RPR)

Outcome Description:

RPR was defined as at least a two-fold increase in the time to repeat paracentesis (TRP) as compared to the average duration of the 2 intervals between the 3 most recent paracenteses prior to study registration (ie, the baseline interval of paracentesis). Percentage of participants with a repeat paracentesis response were the number of participants with RPR / number of total participants * 100.

Outcome Time Frame:

up to 2 years post-registration

Safety Issue:

No

Principal Investigator

ICD

Investigator Role:

Study Director

Investigator Affiliation:

Sanofi

Authority:

United States: Food and Drug Administration

Study ID:

ARD6772

NCT ID:

NCT00396591

Start Date:

October 2006

Completion Date:

November 2008

Related Keywords:

  • Ovarian Neoplasms
  • Ovarian cancer
  • malignant ascites
  • angiogenesis
  • angiogenesis inhibition
  • VEGF-Trap fusion recombinant protein
  • Ascites
  • Neoplasms
  • Ovarian Neoplasms

Name

Location

Sanofi-Aventis Administrative Office Bridgewater, New Jersey  08807